<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731612</url>
  </required_header>
  <id_info>
    <org_study_id>H16-00129</org_study_id>
    <nct_id>NCT02731612</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients</brief_title>
  <acronym>ELICE_BD</acronym>
  <official_title>A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Patients (ELICE-BD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nazlin Walji</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to
      assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression)
      who are in remission from an episode. Participants who show cognitive impairment at the
      screening visit will be enrolled into the study and randomized at the baseline visit to
      receive either lurasidone or placebo adjunctive therapy in a 1:1 ratio for 6 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in cognitive performance in Euthymic bipolar patients treated with Lurasidone vs Placebo adjunctive therapy.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Cognitive improvement will be measured by changes in composite cognitive score from baseline to endpoint, extracted from the International Society for Bipolar Disorders-Battery for Assessment of Neurocognition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Depression</measure>
    <time_frame>6 weeks</time_frame>
    <description>Montgomery Asberg Depression Rating Scale (MADRS) will be used to assess changes in bipolar depression from baseline to endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mania</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Young Mania Rating Scale (YMRS) will be used to assess changes in mania from baseline to endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in overall psychiatric status</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical Global Improvement Scale will be used to assess change from baseline to endpoint in overall psychiatric status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life</measure>
    <time_frame>6 weeks</time_frame>
    <description>Quality of Life, Bipolar Version Scale will be used to assess improvement in quality of life from baseline to endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Subjective-rated Cognitive Functioning</measure>
    <time_frame>6 weeks</time_frame>
    <description>Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) will be used to assess changes in subjective cognitive functioning from baseline to endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Objectively Rated Daily Functioning</measure>
    <time_frame>6 weeks</time_frame>
    <description>Functioning Assessment Short Test (FAST) will be used to assess improvement in objectively rated daily functioning, defined as change in scores from baseline to endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Subjectively Rated Daily Functioning</measure>
    <time_frame>6 weeks</time_frame>
    <description>Sheehan Disability Scale (SDS) will be used to assess improvement in subjectively rated daily functioning, defined as change in scores from baseline to endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo added to current treatment for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lurasidone</intervention_name>
    <description>Atypical Antipsychotic</description>
    <arm_group_label>Lurasidone</arm_group_label>
    <other_name>Latuda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive substance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged 19 to 65 years inclusive.

          2. Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM.5) diagnosis of
             Bipolar Type I or Type II Disorder, with or without a history of psychosis. BP II
             patients must have had 2 definite periods of hypomania in the last 5 years.

          3. All patients must be taking either a mood stabilizer (i.e. lithium or valproate)
             (lamotrigine as a mood stabilizer is acceptable for bipolar 2 disorder patients only
             and not for bipolar I disorder) or an atypical antipsychotic or a combination of these
             (two mood stabilizers or a mood stabilizer plus an atypical antipsychotic), at
             therapeutic doses, for mood stabilization. Those taking two atypical antipsychotics
             are excluded. Combinations of these medications as outlined above, or the combination
             of any of them with lamotrigine 100-400 mg daily, or the combination of a mood
             stabilizer plus asenapine 5-20 mg/day, are also permitted.

          4. All concomitant medication must be at a stable dose for four weeks prior to the
             randomization visit.

          5. Clinically stable during the last 4 weeks as assessed by clinical interview.

          6. A Montgomery Asberg Depression Rating Scale(MADRS) and Young Mania Rating Scale (YMRS)
             score less than or equal to 8.

          7. Patients who show cognitive impairments (-0.50 SD or below) on either the Wechsler
             Adult Intelligence Scale-IV (WAIS-IV) -Coding subtest, or the Rey Auditory Verbal
             Learning Test (RAVLT) total learning score on trials 1 to 5 or immediate recall, at
             screening visit.

          8. A WAIS-IV vocabulary scaled score &gt;5 (equivalent to estimated IQ 80 or greater).

          9. A sufficient level of the English language.

         10. Females who are postmenopausal for at least 1 year before the screening visit
             (confirmed by an FSH test) or are surgically sterile.

         11. Females of childbearing potential who are taking contraceptive pills or agree to
             practice effective double barrier methods of contraception, from the time of signing
             the informed consent up to the last dose of study drug, and for 7 days after dosing
             stops, or who agree to completely abstain from heterosexual intercourse.

         12. Capability of understanding, consenting to, and complying with study requirements,
             study visits, and to return to the clinic for follow-up evaluations as specified by
             the protocol.

        Exclusion Criteria:

          1. A history of unstable or inadequately treated medical illnesses including moderate to
             severe brain injury, or neurological illnesses impacting cognitive function. Patients
             with a personal or family history of cardiac problems will need to undergo
             Electrocardiogram (EKG) at screen visit, and will be excluded if results are abnormal.

          2. Patients taking procognitive medications, clozapine, tricyclic antidepressants,
             first-generation antipsychotics, and cogentin.

          3. Those taking two or more antipsychotics.

          4. Anticholinergics and stimulants that increase dopamine levels are not permitted

          5. Cognitive remediation therapy within 3 months prior to entry or during the double
             blind phase.

          6. Neuromodulation treatment with Electroconvulsive Therapy (ECT) or repetitive
             Transcranial Magnetic Stimulation (rTMS) or transcranial Direct Current Stimulation
             (tDCS) or Deep Brain Stimulation (DBS) within eight weeks or treatment with an
             experimental drug within 30 days.

          7. History of nonresponse or intolerance to lurasidone.

          8. Psychotic disorder other than Bipolar Disorder.

          9. Patients who currently meet criteria for anxiety disorder (General Anxiety Disorder,
             Obsessive Compulsive Disorder, Panic disorder, Post Traumatic Stress Disorder).

         10. Those with a documented childhood diagnosis of Attention-Deficit/Hyperactivity
             Disorder ADHD or other learning disorders.

         11. Axis I diagnosis of alcohol/substance abuse or dependence within the past month.

         12. Significant risk of harm to self or others.

         13. Pregnancy or lactation.

         14. Liver function tests three times the upper limit of normal. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakshmi N Yatham, MBBS, FRCPC, MRCPsych (UK),MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia, Department of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nazlin Walji, B.Sc</last_name>
    <phone>604-822-7294</phone>
    <email>nazlin.walji@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jayasree Basivireddy, PhD</last_name>
    <phone>604-822-3769</phone>
    <email>jayasree.basivireddy@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Brigham and Women's Hospital, Department of Psychiatry</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Shanahan, MHS</last_name>
      <phone>617-732-5790</phone>
      <email>mshanahan2@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Burdick, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Moomaw, BA</last_name>
      <phone>216-844-2863</phone>
      <email>Nicole.Moomaw@UHhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Carla M Conroy, MPH</last_name>
      <phone>216.844.2871</phone>
      <email>Carla.Conroy@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph R Calabrese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UBC Mood Disorders Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayasree Basivireddy, PhD</last_name>
      <phone>604-822-3769</phone>
      <email>jayasree.basivireddy@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Nazlin Walji, BSc.</last_name>
      <phone>604-822-7294</phone>
      <email>nazlin.walji@ubc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Lakshmi N Yatham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Occupational and Environmental Health</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reiji Yoshimura, MD, Ph.D</last_name>
      <phone>81-93-603-1611</phone>
      <email>yoshi621@med.uoeh-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Reiji Yoshimura, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Neuropsychiatry, Kansai Medical University</name>
      <address>
        <city>Moriguchi-shi</city>
        <state>Osaka</state>
        <zip>570-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaki Kato, MD, Ph.D</last_name>
      <phone>81-6-6992-1001</phone>
      <email>masaaki-ogasa@ds-pharma.co.jp</email>
    </contact>
    <investigator>
      <last_name>Masaki Kato, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Hokkaido University Graduate School of Medicine</name>
      <address>
        <city>Kita-ku</city>
        <state>Sapporo</state>
        <zip>060-8638</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ichiro Kusumi, MD., Ph.D</last_name>
      <phone>81-11-706-5160</phone>
    </contact>
    <investigator>
      <last_name>Ichiro Kusumi, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kazuyuki Nakagome, MD, Ph.D</last_name>
      <phone>81-42-341-2711</phone>
      <phone_ext>6200</phone_ext>
      <email>nakagome@guitar.ocn.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuyuki Nakagome, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, Fujita Health University School of Medicine</name>
      <address>
        <city>Aichi</city>
        <state>Toyoake</state>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nakao Iwata, MD, Ph.D</last_name>
      <phone>81-562-93-2000</phone>
    </contact>
    <investigator>
      <last_name>Nakao Iwata, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona, Bipolar Disorder Programme</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Garriga, MD</last_name>
      <phone>932275400</phone>
      <phone_ext>3130</phone_ext>
      <email>MAGARRIGA@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Eduard Vieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Psychiatry, Psychology and Neuroscience,King's College London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 8AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viktoriya Nikolova, BSc MRes</last_name>
      <phone>07795401682</phone>
      <email>viktoriya.nikolova@kcl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Allan Young, MB.ChB, Mphil, PhD,</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Nazlin Walji</investigator_full_name>
    <investigator_title>Certified Clinical Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Cognition</keyword>
  <keyword>Euthymic</keyword>
  <keyword>Lurasidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

